CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 35 enrolled
Drug / intervention
GW786034drug
Likely dose
GW786034 800 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00281632
NCT00281632Phase 2Completed
CompareCT.gov

This Study is a Non-randomized, Open-label, Multi-center Phase II Study of GW786034 to Evaluate the Administration of Oral GW786034 in Subjects With Ovarian Cancer.

GlaxoSmithKline·interventional·Posted Jan 25, 2006·Updated Sep 17, 2018

In Brief

A Phase 2 clinical trial evaluating GW786034 for Peritoneal Cancer and 3 related conditions. Completed, enrolled 35 participants across 10 sites in 3 countries.

Detailed Summary

This study was designed to find out how effective and safe GW786034, is in the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer that has not responded to standard treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer
CountriesAustralia, Singapore, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 25, 2006
Enrollment StartMar 1, 2006
Primary CompletionApr 1, 2008
Study CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 20.4 years ago

Interventions

GW786034drug

800 mg GW786034 administered orally on a daily basis.